The Statistics and Data Management Center (SDMC) is led by three senior principal investigators at Fred Hutch Cancer Center who have extensive experience in multi-center trial operation in prevention, early detection and treatment. This experience in leading statistical and data operations enables us to build an SDMC that will reliably address the analytic needs of the CSRN so that it produces valid evidence about the clinical and population impact of novel early detection products. The SDMC will oversee cancer screening clinical trials enrolling diverse participants, manage and analyze the vast amounts of data generated.
SDMC Leadership
Ziding Feng, PhD
Katherine A. Guthrie, PhD
Charles Kooperberg, PhD
SDMC Primary Aims
SDMC Co-Investigators
David Carrell, PhD
Ruth Etzioni, PhD
Antje Hoering, PhD
Ying Huang, PhD
Catherine Tangen, DrPH
Frequently Asked Questions
- Dr. Charles Kooperberg will be the contact PI of the SDMC. He will be the primary liaison to the CSRN Steering Committee, Coordinating and Communication Center (CCC), ACCESS Hubs, and NCI. Dr. Kooperberg will be responsible for overall study management, oversight, and analysis planning.
- Dr. Katherine Guthrie will oversee data operations and management. She will be the investigator primarily responsible for reporting to the Data and Safety Monitoring Board.
- Dr. Ziding Feng’s primary responsibility will be the statistical aspects of design, analysis, and interpretation of CSRN studies.
The CSRN SDMC’s data management and computing components will be housed at Cancer Research and Biostatistics (CRAB), as they are for the SWOG SDMC. CRAB is an independent non-profit cancer research organization with the mission to prevent and cure cancer using statistical methods and technologies to optimize cancer research assuring the highest research quality and data integrity. For the SWOG SDMC, CRAB collects, manages and maintains trial and correlative data in the CRAB data center for all clinical trials (200+), including the NCI’s Lung-MAP project. CRAB is situated less than a mile from Fred Hutch.
As a cancer screening trials network, the CSRN will conduct multi-center trials of early detection modalities. Therefore, the statistical approach to CSRN studies will incorporate established design and analysis methods for multi-center clinical trials while incorporating the special considerations of screening trials, such as:
- Standard screening trial design and analysis for the primary endpoint of disease-specific mortality.
- Accommodating non-compliance.
- Non-constant mortality rate ratio.
- Shortening trial durations: potential surrogate endpoints.
- The role of modeling
SDMC Suppport Team
Amy Darke, MS
Staff Statistician
Phyllis Goodman, MS
Statistical Analysis Manager
Melissa Plets, MS
Jeannette Schenk, PhD, MS, RD
Project Director
Dani Weatherbee
Applications Development Project Manager